Pharmaceutical News

RSS

Researchers receive $3M grant to develop targeted cancer drugs and repair damaged arteries

The National Institutes of Health has awarded grants totaling $3 million for two nanoparticle research projects in which Penn State bioengineer Jian Yang is co-principal investigator.

19 Feb 2014

Researchers present new drug candidate that selectively kills cancer cells through starvation

In a study published in Nature Communications, researchers at Karolinska Institutet and Uppsala University in Sweden present a new drug candidate, which selectively kills dormant cells within a cancer tumour through starvation.

19 Feb 2014

Matching the right tumor with the right drug

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

19 Feb 2014

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

Update Pharma Inc. today announced that the FDA has approved Orphan Drug Status for the use of UPI-928 for the treatment of Acute Myeloid Leukemia (AML).

18 Feb 2014

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.

18 Feb 2014

NeoStrata announces debut of Vitamin C+ Antiaging Booster

NeoStrata Company, Inc., the creator of the original Glycolic Acid peel, is pleased to announce the debut of Vitamin C+ Antiaging Booster, available February 1, 2014. The NEW dermatologist developed product is the latest and most technologically advanced treatment for helping to smooth wrinkles and brighten dark spots improving skin texture and luminosity.

18 Feb 2014

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Many vaccines, including those for influenza, polio, and measles, consist of a killed or disabled version of a virus. However, for certain diseases, this type of vaccine is ineffective, or just too risky.

18 Feb 2014

Study explains clinical, public health challenges for use of statins in treatment of heart attacks

Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean, and Ira J. Gelb, M.D., emeritus professor of cardiology and senior advisor to the dean for pre-baccalaureate programs at FAU's Charles E. Schmidt College of Medicine, have published an invited editorial in the current issue of Cardiology about the clinical and public health challenges to increase utilization of statins in the treatment and prevention of heart attacks and strokes.

17 Feb 2014

BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with Samyang Biopharmaceutical Corporation granting them the rights to promote, sell and market its novel mucositis management product GelX in the territory of South Korea.

17 Feb 2014

Economy of bodily management responsible for widespread use of illegal steroids among MLB players

The widespread use of illegal steroids among Major League Baseball players has been fueled by an "economy of bodily management," the free agent market and exploding television revenues, a UT Arlington assistant professor argues in a newly published research paper.

16 Feb 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

NCKU research team identifies medicine capable of rejuvenating aged hearts

A southern Taiwan-based National Cheng Kung University (NCKU) research team has identified the critical time period and a drug as treatment for cardiac repairing, the university revealed recently at a press conference.

14 Feb 2014

Topiramate reduces drinking in patients committed to abstinence from alcohol

Heavy drinking alcohol consumption is common in the United States and takes a personal and societal toll, with an annual estimated cost of $223.5 billion due to losses in workplace productivity, and health care and criminal justice expenses.

14 Feb 2014

Two new mechanisms open alternative approaches to antibiotics development

The first mechanism disrupts the arrangement of amino acids required for the cohesion of the protease subunits. As a result the protease breaks into two parts. The second acts directly on the core of the active center.

14 Feb 2014

FDA approves Biologics’ IMBRUVICA as oral agent for treatment of patients with CLL

Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

14 Feb 2014

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

A report in the Feb. 13 New England Journal of Medicine confirms previous studies suggesting that long-term treatment with the type of drugs commonly prescribed to treat restless leg syndrome (RLS) can cause a serious worsening of the condition in some patients.

14 Feb 2014

Prothelia, University of Nevada, Reno and Alexion partner to develop Laminin-111 for MDC1A

Prothelia Incorporated and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein.

13 Feb 2014

Intravenous magnesium fails to improve stroke-related disability

Giving intravenous magnesium to stroke patients soon after the start of symptoms, in an attempt to protect brain cells deprived of oxygen, failed to improve stroke-related disability 3 months later, according to research presented at the American Stroke Association's International Stroke Conference 2014

13 Feb 2014

FDA accepts Regado Biosciences' IND application for REG2

Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.

13 Feb 2014

FDA grants full approval of SYNRIBO for injection

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has granted full approval of SYNRIBO (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA.

13 Feb 2014

Pharmaceutical News

Researchers receive $3M grant to develop targeted cancer drugs and repair damaged arteries

Researchers present new drug candidate that selectively kills cancer cells through starvation

Matching the right tumor with the right drug

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

NeoStrata announces debut of Vitamin C+ Antiaging Booster

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Study explains clinical, public health challenges for use of statins in treatment of heart attacks

BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

Economy of bodily management responsible for widespread use of illegal steroids among MLB players

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

NCKU research team identifies medicine capable of rejuvenating aged hearts

Topiramate reduces drinking in patients committed to abstinence from alcohol

Two new mechanisms open alternative approaches to antibiotics development

FDA approves Biologics’ IMBRUVICA as oral agent for treatment of patients with CLL

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

Prothelia, University of Nevada, Reno and Alexion partner to develop Laminin-111 for MDC1A

Intravenous magnesium fails to improve stroke-related disability

FDA accepts Regado Biosciences' IND application for REG2

FDA grants full approval of SYNRIBO for injection

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News